Snauwaert, S., Vanhee, S., Goetgeluk, G., Verstichel, G., Van Caeneghem, Y., Velghe, I., . . . Vandekerckhove, B. (2012). RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. Ferrata Storti Foundation.
Παραπομπή Chicago StyleSnauwaert, Sylvia, et al. RHAMM/HMMR (CD168) Is Not an Ideal Target Antigen for Immunotherapy of Acute Myeloid Leukemia. Ferrata Storti Foundation, 2012.
Παραπομπή MLASnauwaert, Sylvia, et al. RHAMM/HMMR (CD168) Is Not an Ideal Target Antigen for Immunotherapy of Acute Myeloid Leukemia. Ferrata Storti Foundation, 2012.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.